Lavanya Lokhande

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 5

Top Topics

Acute Lymphoblastic Leukemia

Top Venues

Cancer reports (Hoboken, N.J.)

This page only lists publications with an associated author ORCID identifier.

Publications

Joana Matos Rodrigues, Lavanya Lokhande, Lina Maj Olsson, May Hassan, Angelica Johansson, Anna Janská, Darshan Kumar, Lina Schmidt, Anna Nikkarinen, Peter Hollander, Ingrid Glimelius, Anna Porwit, Anna Sandström Gerdtsson, Mats Jerkeman, Sara Ek
CD163+ macrophages in mantle cell lymphoma induce activation of prosurvival pathways and immune suppression. Blood advances 8 (16) (2024)
Joana Matos Rodrigues, Lavanya Lokhande, Lina Maj Olsson, May Mostafa Hassan, Angelica Johansson, Anna Janská, Darshan Kumar, Lina Schmidt, Anna Nikkarinen, Peter Hollander, Ingrid Glimelius, Anna Porwit, Anna Sandström Gerdtsson, Mats Jerkeman, Sara Ek
CD163+ macrophages in mantle cell lymphoma induce activation of pro-survival pathways and immune suppression. Blood advances (2024)
Joana Matos Rodrigues, Lavanya Lokhande, Lina Maj Olsson, May Hassan, Angelica Johansson, Anna Janská, Darshan Kumar, Lina Schmidt, Anna Nikkarinen, Peter Hollander, Ingrid Glimelius, Anna Porwit, Anna Sandström Gerdtsson, Mats Jerkeman, Sara Ek
CD163+ macrophages in mantle cell lymphoma induce activation of prosurvival pathways and immune suppression. Blood advances 8 (16) (2024)
Anna Nikkarinen, Lavanya Lokhande, Rose-Marie Amini, Mats Jerkeman, Anna Porwit, Daniel Molin, Gunilla Enblad, Arne Kolstad, Riikka Katariina Räty, Martin Hutchings, Caroline E Weibull, Peter Hollander, Sara Ek, Ingrid Glimelius
Soluble CD163 predicts outcome in both chemoimmunotherapy and targeted therapy-treated mantle cell lymphoma. Blood advances (2023)
Lavanya Lokhande, Venera Kuci Emruli, Christian Winther Eskelund, Arne Kolstad, Martin Hutchings, Riikka Räty, Carsten Utoft Niemann, Kirsten Grønbaek, Mats Jerkeman, Sara Ek
Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma. Cancer reports (Hoboken, N.J.) (2021)